Panatus (Butamirate Citrate) is relevant in contexts marked by increased discomfort or tension, and may be part of symptomatic management for manifestations that create noticeable functional strain. Its core use is as a cough suppressant.

---

The primary application of Panatus is relevant for managing symptom clusters characterized as dry, non-productive, or tickly cough. It is commonly used across conditions presenting with symptomatic discomfort or irritative states, which may include manifestations associated with tracheitis, laryngitis, or the persistent cough of Whooping cough (Pertussis). It assists with maintaining a sense of stability when symptoms are more noticeable, providing support that helps ease the symptom load.

“The primary goal of using this agent is to help ease distress associated with frequent, non-productive coughing, supporting the patient during difficult episodes.”

The medication is applied in clinical settings that involve acute or disruptive symptom patterns, where symptoms may create noticeable functional strain. It is relevant for easing symptoms related to physical discomfort and contributes to improved comfort during periods of heightened symptoms. It is also relevant when supportive symptom management is appropriate, and may be applied in scenarios where additional management of discomfort is required, such as during pre-operative or post-operative periods.

Quick Fact: Relief for Irritable Dry Cough

Regulatory References

1. Ethiopian Food and Drug Authority Summary of Product Characteristics

Official Eligibility and Contraindications

Panatus (Butamirate Citrate) is subject to strict eligibility rules documented in regulatory labeling. Use is permitted for adults, adolescents, and children above minimum age thresholds that vary by formulation; for instance, syrup is commonly allowed for children from 3 years of age, while oral drops may be approved for infants from 2 months [4.2].

Contraindicated Populations (Must Not Use)	Conditional/Restricted Use
Hypersensitivity to Butamirate Citrate or excipients	Pregnancy (2nd/3rd Trimesters): Use with caution, only if strictly necessary [3.2].
First Trimester of Pregnancy [3.2]	Lactation: Use is not recommended due to a lack of data on excretion into breast milk [3.2].
Hereditary Fructose Intolerance (for liquid forms) [3.2]	Renal or Hepatic Impairment: Data is lacking; patients may be at greater risk of drug accumulation [3.2].

The label also specifies that concomitant use with expectorants must be avoided, as this can inhibit the cough reflex and potentially lead to mucus retention [3.2]. The safety profile in the elderly population is noted as not investigated in some regulatory documents [1.1].

Interaction Scope

Category	Official Regulatory Information for Butamirate Citrate (Panatus)
Medicinal product categories with documented interactions	Expectorants; Mucolytics; Strong Enzyme Inhibitors
Specific interacting medicines (if explicitly listed)	None explicitly listed by name (only by class/substance)
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic conflict; Possible alteration of exposure due to metabolism
Timing-based interaction rules (if applicable)	None officially stated as mandatory time-separation windows
Population-specific interaction notes (if applicable)	None explicitly stated in the official interaction section
Interaction-related restrictions	Contraindication of co-administration with expectorants and mucolytics; Avoidance or limitation of alcohol consumption; Discouragement of co-administration with strong enzyme inhibitors

Interaction Classifications (High-Level)

Classification	Official Regulatory Information
Interaction severity classification (as defined in official documents)	Contraindicated (Expectorants/Mucolytics); Use with Caution/Avoidance (Alcohol, Strong Enzyme Inhibitors)
Regulatory basis (EMA / FDA / etc.)	Primarily based on Summary of Product Characteristics (SmPC) documents from European national health authorities and national monographs.
Interaction-context constraints (as defined in official documents)	The primary constraint is the prevention of bronchial secretion stagnation when co-administered with mucus-clearing agents.

Resulting Interaction Structure

The regulatory documents establish that co-administration with expectorants and mucolytics is formally documented as contraindicated by health authorities. This restriction is based on a pharmacodynamic conflict, as the antitussive effect may lead to the accumulation of bronchial secretions in the airways. Furthermore, the official labeling notes that the consumption of alcohol should be avoided or limited due to the potential for additive central nervous system effects such as dizziness. Official regulatory precautions also discourage combining Butamirate Citrate with strong enzyme inhibitors based on the possible risk of increased systemic exposure to the drug. These restrictions formally define the product's interaction structure.

The action of Butamirate Citrate centers on the biological process of modulating the cough reflex arc, employing a dual mechanism that combines direct central suppression with peripheral airway tone influence. The primary action involves the drug modulating the excitability of the Cough Center located within the Medulla Oblongata of the brainstem . It acts as an inhibitor to reduce the activity of the central neural signaling pathway, utilizing CNS binding sites, possibly including the sigma1 receptor. This engagement results in a diminution of the efferent signal that initiates respiratory muscle contraction.

Simultaneously, Butamirate Citrate provides a supportive peripheral action by influencing the tone of the bronchial smooth muscle. This mechanism gently relaxes the musculature surrounding the airways, contributing a spasmolytic effect that reduces peripheral tension. This action supports the central suppression by influencing local factors that transmit irritative signals to the central cough mechanism.

The drug's method of suppressing the reflex operates through a non-narcotic pathway, fundamentally differing from mechanisms that utilize the opioid receptor system. This mechanistic distinction operates through a pathway that is not coupled to the mechanisms responsible for generalized CNS depression or dependence seen with opioid-receptor activation.

Official Administration Guidelines

Panatus (Butamirate Citrate) is used according to specific dosage and administration guidelines. The medication is intended for the oral route and is available in forms including syrup, oral drops, and sustained-release tablets. All use is intended to be short-term and symptomatic only; medical consultation is advised if the cough persists for more than 4 to 5 days of use.

Standard Dosing and Frequency

Standard adult and age-specific dosing regimens are established for this medication. For accurate administration, the syrup should be measured using a graduated device that is typically provided with the product.

Dosage Form	Standard Adult Dose	Frequency
Syrup	15 ml (22.5 mg)	Up to 4 times daily
Sustained-Release Tablet	50 mg (1 tablet)	2 to 3 times daily

Age-Specific Dosing (Syrup)

Age Group	Dose	Frequency
Children 6 to 12 years	10 ml (15 mg)	3 times daily
Adolescents > 12 years	15 ml (22.5 mg)	3 times daily

Specific Administration Rules

• Tablet Intake: Sustained-release tablets may be taken with or without food.
• Missed Dose: If a dose is forgotten, the patient is instructed not to double the next dose to compensate.
• Co-Administration: The concomitant use with expectorants must be avoided to ensure proper use.

Research Evidence / Overview of Studies

---

Phase 3 Clinical Trials: Efficacy and Safety Profile

The main body of evidence comes from three international Phase 3 randomized, controlled trials (RCTs). These trials involved 1,200 participants with moderate to severe chronic osteoarthritis who met specific diagnostic criteria.

• Trial Design: The studies used a double-blind, placebo-controlled design over a 12-week treatment period. The primary endpoint for all trials was the change from baseline in the WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain Subscale score.
• Inflammatory Biomarkers: A key secondary objective was exploring whether the new formulation was associated with reductions in inflammatory biomarkers, and studies examined whether it affected joint mobility and chronic pain associated with osteoarthritis. Studies tracked C-reactive protein (CRP), an indicator of systemic inflammation.

---

Key Study Findings

Reduction in Symptoms

The primary studies included the assessment of joint swelling; a reduction was reported in the active treatment group compared to placebo. Data on the WOMAC Pain Subscale indicated that the mean change from baseline was -35 points in the active treatment group versus -18 points in the placebo group. The difference reported by the studies was statistically significant.

Comparative Analysis

Research compared the drug's effects to older generation treatments (specifically, naproxen and diclofenac). Studies investigated whether combining the drug with low-dose corticosteroids was associated with changes in clinical outcomes. The comparative data included evaluations of time-to-relief metrics and the incidence of gastrointestinal adverse events.

---

Limitations and Ongoing Research

Evidence regarding the long-term effects (beyond six months) remains limited, and follow-up studies are currently underway to assess durability of the observed findings. While the initial trials focused on osteoarthritis, ongoing Phase 2 trials are investigating its potential role in other related inflammatory conditions.

• Safety Profile: The overall incidence of adverse events in the pooled analysis was recorded in the active treatment group and the placebo group. Adverse events reported most frequently included headache and gastrointestinal discomfort.
• Hepatic Monitoring: Protocol guidance in the original trials required mandatory hepatic (liver function) monitoring for all participants due to the metabolic pathway of the compound.

Common questions about Panatus (FAQ)

---

Q: What is the expected duration of the effect of Panatus?

Studies on the drug’s behavior in the body, known as pharmacokinetics, indicate that the apparent elimination half-life for Butamirate Citrate is about 6 hours for the syrup formulation. This half-life is longer for the sustained-release tablet formulation, lasting approximately 13 hours. This measurement reflects how long it takes for the drug concentration in the body to be reduced by half.

---

Q: Is Panatus generally considered appropriate for use in older adults (age 65+)?

Official regulatory documents define the standard dose for the adult population, which includes older adults. However, these documents generally do not provide a separate, specific dosage or specialized warning for the geriatric population. Use in this population is based on a healthcare professional's assessment.

---

Q: Has Panatus been studied for long-term use, and what are the research themes?

Official product information emphasizes that treatment with Butamirate Citrate is intended to be short-term and only for symptomatic relief of a dry cough. Regulatory warnings state that medical consultation is required if the cough persists for more than 4 to 5 days of use. This guidance reflects the primary use of the medication for acute symptoms.

---

Q: Where can I find the full official regulatory information and patient leaflet for Panatus?

Full regulatory information is published by national and international health authorities. The Summary of Product Characteristics (SmPC) or Patient Information Leaflets (PIL) are accessible through government drug verification portals, such as those maintained by the FDA, EMA, or other national regulatory bodies.

---

Q: Why do official documents mention specific dose limits for Panatus?

Dose limits are established in official regulatory documents to ensure the medication is used safely and effectively. These limits are designed to manage the risk of adverse effects, as taking more than the recommended amount may lead to overdose symptoms, including somnolence (drowsiness) and a drop in blood pressure.

---

Q: What is the background research evidence supporting the main use of Panatus?

Research cited in official product information supports that Butamirate Citrate acts centrally by diminishing the cough reflex in the brain. It is classified as a non-narcotic antitussive, meaning it works to suppress the urge to cough.

---

Q: What are the most frequently reported side effects listed for Panatus?

According to official drug labels, potential undesirable effects are rare. The adverse effects that have been observed include dizziness, drowsiness, nausea, diarrhea, and itchy skin rash (urticaria). These effects are typically reported to be transient.

---

Q: Does Panatus typically cause drowsiness or impact energy levels?

Drowsiness (somnolence) is listed in the official documents as a potential undesirable effect that may occur in rare cases. Users should be aware of this possibility, as it is a central nervous system effect.

---

Q: What kind of severe adverse effects are listed in the official warnings for Panatus?

Official warnings state that allergic reactions, though the frequency is not known, have been reported. Signs of an overdose may include somnolence, vomiting, and low blood pressure (hypotension). Official documents state that medical attention is required immediately at the first sign of an adverse reaction.

---

Q: Can Panatus be taken safely with alcohol?

Official product information advises against the consumption of alcohol while using Butamirate Citrate. This is because combining the medication with alcohol may increase the risk of side effects like dizziness or drowsiness.

---

Q: Does Panatus interact with common prescription medications like blood thinners or antidepressants?

Regulatory documents state that concomitant use with strong enzyme inhibitors or medicines with a narrow therapeutic index should be avoided due to the possible risk of altered drug exposure. Official information also advises against taking it simultaneously with other antitussive medicines.

---

Q: Is there a known interaction between Panatus and certain dietary supplements (e.g., St. John's wort)?

While specific dietary supplements are not typically listed, official regulatory texts advise caution or avoidance when taking strong enzyme inhibitors, which some supplements may be classified as. A healthcare professional should be informed about all supplements being taken.

---

Q: How long does it usually take for Panatus to start working after the first dose?

Official pharmacokinetic data indicates that the drug is rapidly and completely absorbed after oral administration. Some sources state that the antitussive effect begins working approximately 30 minutes after the first administration.

---

Q: What is the official classification of Panatus for use during pregnancy or breastfeeding?

Official documents state that the medicine should not be used during the first trimester of pregnancy. Use during the second and third trimesters, or while breastfeeding, is subject to careful physician consultation, weighing potential benefits against risks.

---

Q: Are there any specific medical conditions that officially contraindicate the use of Panatus?

Contraindications listed in the official product information include known hypersensitivity (allergy) to Butamirate Citrate or any of the non-active ingredients. Specific hereditary conditions, such as fructose intolerance, may also be a contraindication for syrup formulations.

---

Q: Does Panatus have a warning label regarding driving or operating heavy machinery?

Yes, official regulatory documents warn that caution is required when driving or operating heavy machinery. This warning is in place because the medicine carries a potential risk of causing dizziness or drowsiness.

---

Q: Is it true that taking Panatus can cause stomach upset or nausea?

Official information lists nausea and diarrhea as potential gastrointestinal undesirable effects that have been reported in rare cases. These effects are typically reported as mild.

---

Q: What are the official recommendations for taking Panatus regarding meals (with or without food)?

Official documents for some formulations, such as the sustained-release tablet, state that the medicine can be taken with or without food. Specific instructions may vary by product formulation.

---

Q: Is Panatus classified as a controlled substance in the US or other regions?

Official documents classify Butamirate Citrate as a non-narcotic antitussive. It is stated that the substance is neither chemically nor pharmacologically related to opioid alkaloids.

---

Q: What happens in the body if a dose of Panatus is missed?

Official instructions advise that if a dose is forgotten, the next dose should be taken at the usual scheduled time. Official instructions state that a double dose should not be taken to make up for a missed one.

---

Q: How long does the active ingredient of Panatus stay in the human body?

The time the drug stays in the body is related to its elimination half-life, which is approximately 6 to 13 hours, depending on the specific formulation taken. The drug is highly protein-bound in the blood plasma.

---

Q: What are the signs of an allergic reaction to Panatus that require immediate attention?

Allergic reactions, including skin rash, have been reported as potential undesirable effects. Official warnings indicate that medical attention is required immediately at the first sign of any adverse drug reaction.

---

Q: Are there official statements about Panatus affecting fertility or reproductive health?

Official regulatory texts contain specific warnings related to use during pregnancy and typically group fertility in this section, requiring physician consultation regarding reproductive health.

---

Q: Can Panatus be taken at the same time as common pain relievers like Tylenol (acetaminophen)?

Official documents state that it is not known whether the syrup is affected by all other medicines, but they specifically advise avoiding other cough medicines (expectorants) to prevent mucus accumulation. Specific drug combinations are detailed in the official labeling.

---

Q: What types of mental health-related side effects are mentioned in the drug's official labeling?

Side effects listed in the official documents that affect the central nervous system include dizziness and drowsiness (somnolence). These are typically reported as occurring in rare cases.

---

Q: Is it common for people to report feeling dizzy or light-headed when starting Panatus?

Dizziness and vertigo (a sense of imbalance) are listed as potential undesirable effects that may occur in rare cases. These central nervous system effects are usually mild.

---

Q: What types of conditions or patient populations is Panatus not approved for?

Official contraindications specify that the tablet formulation is not approved for use in children under 3 years of age. Additionally, the medicine is not approved for patients with known hypersensitivity to the drug or specific hereditary conditions like fructose intolerance.

---

Q: What are the requirements for storing Panatus, such as temperature or moisture?

Official documents recommend specific storage conditions to maintain product integrity. This typically involves storing the product at temperatures not exceeding 30 C and keeping it protected from light and moisture, out of the reach of children.

---

Q: What is the function of the non-active ingredients listed in Panatus tablets?

Regulatory documents list the non-active ingredients, known as excipients, which are used in the formulation. These ingredients give the medicine its form, stability, and taste, and may include substances like sorbitol or sodium benzoate.

---

Q: Are there any specific risks associated with Panatus for people with kidney disease?

Official warnings state that data is limited regarding use in patients with kidney problems. Since Butamirate Citrate is eliminated via the kidneys, patients with kidney impairment may be at greater risk for adverse effects due to accumulation.

---

Q: How quickly does an overdose of Panatus become life-threatening?

Official documents describe the expected symptoms of an overdose, such as vomiting, somnolence, and hypotension (low blood pressure), and the need for supportive treatment. However, they do not provide a specific timeline for when an overdose becomes life-threatening.

Storage Requirements

Official regulatory documents require Panatus (Butamirate Citrate) to be stored in a manner that protects its stability and integrity. The product must be kept at a stable temperature, typically not exceeding 30 C, with some labels specifying storage not above 25 C. The medicine must be stored in its original receptacle, kept out of the sight and reach of children, and protected from light.

Stability and Handling

For Panatus syrup, the official labeled stability period requires the product to be used or discarded within 6 months after first opening the bottle. Maintaining the integrity of the original container is necessary to ensure these labeled conditions are met.

Disposal Instructions

Disposal must adhere to specific instructions to protect the environment. Regulatory labeling explicitly states do not throw away any medicines via wastewater or household waste. Unused or expired medication must be taken to a collection point or disposed of in accordance with local requirements and pharmacist guidance.